TW202333789A - 一種包含抗ＦＸＩ／ＦＸＩａ抗體的醫藥組成物及其用途 - Google Patents

一種包含抗ＦＸＩ／ＦＸＩａ抗體的醫藥組成物及其用途 Download PDF

Info

Publication number
TW202333789A
TW202333789A TW112100422A TW112100422A TW202333789A TW 202333789 A TW202333789 A TW 202333789A TW 112100422 A TW112100422 A TW 112100422A TW 112100422 A TW112100422 A TW 112100422A TW 202333789 A TW202333789 A TW 202333789A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
fxi
sucrose
antigen
binding fragment
Prior art date
Application number
TW112100422A
Other languages
English (en)
Chinese (zh)
Inventor
沈立君
趙志龍
李磊
湯辰翔
Original Assignee
大陸商上海邁晉生物醫藥科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商上海邁晉生物醫藥科技有限公司 filed Critical 大陸商上海邁晉生物醫藥科技有限公司
Publication of TW202333789A publication Critical patent/TW202333789A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
TW112100422A 2022-01-05 2023-01-05 一種包含抗ＦＸＩ／ＦＸＩａ抗體的醫藥組成物及其用途 TW202333789A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202210006206.X 2022-01-05
CN202210006206 2022-01-05
CN202210053441.2 2022-01-18
CN202210053441 2022-01-18

Publications (1)

Publication Number Publication Date
TW202333789A true TW202333789A (zh) 2023-09-01

Family

ID=87073189

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112100422A TW202333789A (zh) 2022-01-05 2023-01-05 一種包含抗ＦＸＩ／ＦＸＩａ抗體的醫藥組成物及其用途

Country Status (6)

Country Link
US (1) US20250179213A1 (https=)
EP (1) EP4461749A4 (https=)
JP (1) JP2025502861A (https=)
CN (1) CN118382643A (https=)
TW (1) TW202333789A (https=)
WO (1) WO2023131213A1 (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11066481B2 (en) * 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
TW201802121A (zh) * 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
US20190367636A1 (en) * 2017-01-19 2019-12-05 Bayer Pharma Aktiengesellschaft Novel stable formulation for fxia antibodies
EP3626266A4 (en) * 2017-05-16 2021-04-07 Jiangsu Hengrui Medicine Co., Ltd. CTLA4 ANTIBODY PHARMACEUTICAL COMPOSITION AND USES THEREOF
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
PE20210462A1 (es) * 2018-07-05 2021-03-08 Bayer Ag METODO PARA LA PRODUCCION DE GRANULOS LIOFILIZADOS QUE COMPRENDEN UN ANTICUERPO ANTI-FACTOR XIa (FXIa) DE LA COAGULACION
CN110732023B (zh) * 2018-07-18 2023-06-16 江苏恒瑞医药股份有限公司 一种her2抗体药物组合物及其用途
EP3898700A1 (en) * 2018-12-18 2021-10-27 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
KR20210151774A (ko) * 2019-04-16 2021-12-14 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항-FXI/FXIa 항체 및 그 용도
US20230071973A1 (en) * 2019-12-20 2023-03-09 Anthos Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
EP4177274A4 (en) * 2020-07-02 2024-04-03 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof

Also Published As

Publication number Publication date
EP4461749A1 (en) 2024-11-13
JP2025502861A (ja) 2025-01-28
CN118382643A (zh) 2024-07-23
US20250179213A1 (en) 2025-06-05
EP4461749A4 (en) 2025-03-26
WO2023131213A1 (zh) 2023-07-13

Similar Documents

Publication Publication Date Title
TWI829799B (zh) 一種TGF-β受體融合蛋白醫藥組成物及其用途
CN110538321B (zh) 一种cd47抗体药物组合物及其用途
EP3714901A1 (en) Lag-3 antibody pharmaceutical composition and use thereof
JP2026048838A (ja) 高濃度抗ｃ５抗体配合物
CN109952093B (zh) 一种sost抗体药物组合物及其用途
CN110960490A (zh) 一种抗egfr抗体偶联药物组合物及其用途
WO2022022660A1 (zh) 抗pd-1抗体药物组合物及其用途
WO2020200099A1 (zh) 包含抗il-5抗体的药物组合物及其用途
WO2020043095A1 (zh) 一种tim3抗体药物组合物及其用途
US20240352113A1 (en) Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its application
TW201904609A (zh) 一種pcsk-9抗體醫藥組成物及其用途
TW202333789A (zh) 一種包含抗ＦＸＩ／ＦＸＩａ抗體的醫藥組成物及其用途
TW202432176A (zh) 一種抗masp2抗體的組成物及醫藥用途
HK40045548A (en) TGF-β RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF
HK40009387A (en) Sost antibody pharmaceutical composition and uses thereof
HK40009387B (en) Sost antibody pharmaceutical composition and uses thereof
HK40047597A (en) Anti-tim3 antibody pharmaceutical composition and use thereof
HK40025348A (en) Lag-3 antibody pharmaceutical composition and use thereof